propranolol + trastuzumab

This is a combination of two drugs, propranolol and trastuzumab, investigated primarily in the context of HER2-positive breast cancer. Propranolol is a non-selective beta-adrenergic receptor antagonist (beta-blocker) commonly used for cardiovascular conditions but has shown potential anti-tumor and anti-metastatic effects in preclinical and clinical studies. Trastuzumab is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), approved for the treatment of HER2-positive breast cancer. The rationale for combining these agents stems from evidence that beta-adrenergic signaling may promote tumor progression and resistance to therapies like trastuzumab; thus, propranolol could potentially enhance or modify the efficacy of trastuzumab by inhibiting stress-related pro-tumor pathways. Clinical data are mixed regarding survival outcomes with this combination, with some retrospective studies suggesting improved progression-free survival (PFS) and overall survival (OS), while others indicate possible negative effects or no significant benefit[1][2][7].